Reply: Adalimumab-associated pulmonary fibrosis [6]

Rheumatology

Volumn 46, Issue 8, 2007, Pages 1379-1380

  Collins, K ^a   Todd, A ^a   Rynne, M ^a   Hamilton, J ^a   Saravanan, V ^a   Kelly, Clive ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

BRONCHIECTASIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DYSPNEA; FIBROSING ALVEOLITIS; GAS DIFFUSION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; LETTER; LUNG FIBROSIS; LUNG FUNCTION TEST; MONOTHERAPY; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT INDICATION; VITAL CAPACITY;

EID: 34547851815     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem142     Document Type: Letter

References (4)

1. Huggett MT, Armstrong R. Adalimumab associated pulmonary fibrosis. Rheumatology 2006;45:1312-3.
2. Ed. Clive Kelly. Lung disease in rheumatic disorders. Baillieres Clinical Rheumatology 1993;7:1.
3. Howse M, Tose J, White C, Kumar N, Heycock C, Kelly CA. Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis? Internal Medicine 1999;7:51-4.
4. Saravanan V, Kelly CA. Drug related pulmonary problems in patients with rheumatoid arthritis. Editorial Rheumatology 2006;45:787-90.